Yes, Dupixent Treats Both Asthma and Eczema
Dupixent (dupilumab) is FDA-approved for moderate-to-severe atopic dermatitis (eczema) in adults and children as young as 6 months, and for moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent cases in patients 6 years and older.[1]
How Dupixent Works for Eczema
It blocks IL-4 and IL-13 signaling, cytokines driving type 2 inflammation in eczema. Patients inject it every two to four weeks after loading doses, reducing itch and rash severity in clinical trials where over 70% achieved clear or almost clear skin.[1]
How Dupixent Works for Asthma
For asthma, it targets the same IL-4/IL-13 pathway to cut exacerbations by up to 67% and improve lung function in trials, especially for patients with high eosinophil counts or allergies.[1]
Other Approved Uses
Dupixent also treats chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with type 2 inflammation.[1]
Common Side Effects Across Conditions
Injection-site reactions, conjunctivitis, and joint pain occur in 10-20% of users; serious infections or hypersensitivity are rare but monitored.[1]
[1] https://www.dupixent.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dupilumab-dupixent-information